Pre-eclampsia is a medical condition that affects one in twenty pregnancies and can lead to various complications for the mother and child, including stroke, seizures, or even death. Pre-eclampsia can be diagnosed during the second trimester and occurs when the mother develops hypertension, i.e. high blood pressure, or unusually high concentrations of protein in her urine. While there is currently no treatment for pre-eclampsia, a recent study published in Reproductive Sciences could help identify those women at risk for developing pre-eclampsia.
The article, titled “Placental Protein 13 and Decidual Zones of Necrosis: An Immunologic Diversion That May be Linked to Preeclampsia,” was published by Harvey J. Kliman, MD, PhD, a research scientist operating out of Yale University, and several other scientists. The article focused on recent findings Kilman and his colleagues had unearthed about the role of Placental Protein 13 (PP13) and what this could mean for pre-eclampsia patients.
PP13 is a protein made by the placenta during pregnancy. Prior research had found PP13 levels to be very low among women who develop pre-eclampsia; however, the role of PP13 in pregnancy had previously been unknown. In the present study, the doctors studied placentas from normal pregnancies that had been terminated prior to the 14th week of gestation. They not only found the PP13 to be concentrated in maternal tissue surrounding the veins running under the placenta, but also found a high degree of necrotic maternal tissue in the same area.